infect
host
cell
proce
revers
transcript
viral
dna
integr
host
genom
transcript
translat
proteolyt
process
viral
protein
subsequ
assembl
nascent
viral
particl
larg
extent
introduct
combin
antiretrovir
treatment
cart
curtail
viral
replic
detect
limit
copiesml
significantli
reduc
devast
impact
cart
work
block
infect
suscept
new
cell
decay
rate
plasma
viru
determin
life
span
previous
infect
cell
howev
given
presenc
intact
reservoir
includ
quiescent
lymphocyt
bone
marrow
brain
well
develop
viral
escap
mutant
drug
resist
viral
replic
goe
uncheck
intens
therapi
treat
patient
full
viral
suppress
actual
lowlevel
steadyst
viremia
given
long
durat
treatment
viru
develop
drug
resist
multipl
step
result
treatment
failur
transactiv
transcript
tat
protein
engag
posit
transcript
elong
factor
b
ptefb
complex
increas
rna
pol
ii
activ
drive
viral
transcript
elong
tat
activ
enhanc
host
factor
tatassoci
histon
acetylas
tah
pcaf
well
acetyl
tat
ly
pcaf
acetyl
ly
tat
increas
abil
recruit
ptefb
complex
thu
tat
import
therapeut
target
abil
interrupt
viral
life
cycl
coincident
effect
transcript
inhibitor
yet
avail
complement
cart
thu
altern
keep
viru
underexpress
state
infect
cell
die
inhibit
transcript
subsequ
viral
protein
synthesi
requir
new
inhibitor
flavon
class
flavonoid
contain
characterist
ring
structur
fig
found
mani
herb
shown
therapeut
valu
includ
antivir
antiinflammatori
properti
luteolin
myricetin
quercetin
structur
relat
flavon
fig
act
antioxid
freerad
scaveng
dramat
reduc
inflammatori
respons
antioxid
properti
relat
number
posit
hydroxyl
group
luteolin
occur
parsley
artichok
leav
celeri
pepper
oliv
oil
rosemari
lemon
peppermint
sage
thyme
act
antioxid
antivir
agent
use
clinic
trial
inhibit
neuroinflamm
luteolin
also
found
activ
although
luteolin
promot
carbohydr
metabol
immun
system
modul
shown
potent
antiinflammatori
activ
inhibit
nuclear
factor
kappa
b
nfkb
macrophag
immun
cell
addit
luteolin
shown
effect
sar
coronaviru
studi
use
recombin
pseudotyp
sar
cov
envelop
anoth
studi
found
proteas
inhibitor
activ
cellfre
assay
valid
infect
studi
moreov
precis
mechan
inhibit
unclear
flavonoid
quercetin
myricetin
luteolin
structur
close
relat
use
dietari
supplement
unit
state
also
investig
activ
possibl
mechan
action
although
found
three
flavonoid
nontox
activ
luteolin
potent
inhibit
infect
abrog
tatmedi
ltr
activ
given
longterm
persist
intact
reservoir
along
develop
viral
escap
mutant
drug
resist
viral
replic
goe
uncheck
even
intens
therapi
uninterrupt
lifelong
anti
treatment
result
longer
surviv
persist
residu
viral
activ
immun
activ
carttreat
individu
develop
minor
cognit
disord
addit
antihiv
treatment
lead
immun
reconstitut
inflammatori
syndrom
iri
substanti
number
african
patient
develop
drug
resist
commonli
encount
treatment
thu
continu
search
new
therapeut
agent
target
novel
viral
life
cycl
stage
need
use
natur
occur
compound
dietari
supplement
antioxid
properti
potenti
provid
attract
therapi
combin
cart
investig
abil
flavonoid
compound
fig
alter
activ
screen
assay
use
ltrluciferas
tzmbl
report
cell
primari
lymphocyt
infect
model
tzmbl
cell
hela
cell
stabli
express
receptor
contain
integr
copi
long
termin
repeat
ltr
fuse
luciferas
beta
galactosidas
gene
express
indic
luciferas
gene
control
ltr
via
transactiv
tat
protein
synthes
either
viral
infect
plasmid
express
vector
tzmbl
cell
treat
min
luteolin
quercetin
myricetin
concentr
infect
fortyeight
hour
later
infect
report
cell
monitor
ltr
activ
use
luciferas
report
assay
intriguingli
flavonoid
compound
concentr
show
activ
luteolin
potent
fig
inhibit
luteolin
specif
vehicl
control
dmso
effect
ltr
activ
rule
interfer
toxic
monitor
cell
viabil
flavonoid
treatment
use
assay
tzmbl
cell
none
compound
show
cellular
cytotox
concentr
fig
although
luteolin
show
slight
toxic
tzmbl
report
cell
found
verif
hela
jurkat
cell
fig
lymphocyt
rel
nontox
toxic
luteolin
tzmbl
cell
could
result
presenc
multipl
stabl
construct
cell
moreov
earlier
studi
sever
cell
system
report
luteolin
concentr
advers
effect
data
suggest
flavonoid
activ
inhibit
activ
possibl
malfunct
tat
activ
could
due
blockag
step
viral
life
cycl
studi
examin
activ
luteolin
greater
detail
test
differ
concentr
luteolin
cell
viabil
differ
cell
model
find
workabl
nontox
concentr
luteolin
concentr
upper
limit
therapeut
agent
use
screen
assay
signific
antivir
activ
thu
use
luteolin
experi
fig
confirm
activ
luteolin
infect
assay
lymphocyt
cell
primari
human
lymphocyt
use
either
wildtyp
vsvpseudotyp
infect
studi
use
contain
gfp
gene
clone
envelop
nef
region
thu
could
monitor
product
viral
gene
express
gfp
express
use
fluoresc
microscopi
capsid
protein
supernat
detect
elisa
jurkat
cell
pretreat
luteolin
vehicl
dmso
min
follow
infect
report
earlier
infect
luteolin
treatment
maintain
day
durat
experi
luteolin
treatment
markedli
reduc
infect
jurkat
cell
fig
dosedepend
manner
shown
reduct
number
gfpposit
cell
viral
releas
supernat
fifth
day
infect
confirm
find
also
rule
inhibit
infect
tzmbl
cell
obtain
similar
suppress
viral
infect
fig
although
treatment
luteolin
prior
infect
addit
advantag
viru
replic
compar
overnight
treatment
infect
fig
instead
better
inhibit
seen
latter
indic
luteolin
may
affect
later
stage
life
cycl
rather
restrict
viru
receptor
revers
transcript
viral
dna
integr
step
test
possibl
infect
studi
primari
human
lymphocyt
use
wild
type
viru
addit
use
facilit
rapid
homogen
receptorindepend
viral
infect
studi
confirm
luteolin
nontox
primari
cell
fig
treat
wildtyp
infect
lymphocyt
luteolin
followup
monitor
viral
infect
gfp
express
releas
cultur
supernat
fig
luteolin
treatment
allevi
infect
vsvhiv
shown
reduct
gfp
express
fig
level
supernat
follow
viru
releas
day
infect
fig
parallel
dichloro
drb
transcript
inhibitor
rna
pol
ii
inhibitor
use
posit
control
vehicl
dmso
use
solvent
control
drb
suppress
transcript
inhibit
rna
polymeras
activ
interestingli
luteolin
treatment
infect
lymphocyt
also
show
inhibit
cell
aggregationsyncytia
similar
produc
drb
cell
control
fig
suggest
viral
envelop
protein
express
cell
surfac
impair
viral
express
infect
cell
requir
syncytia
format
aggreg
cell
addit
luteolin
affect
prolifer
lymphocyt
viral
inhibit
studi
result
thu
far
indic
mechan
luteolinmedi
suppress
independ
viral
entri
receptor
corrobor
effect
luteolin
viru
tzmbl
report
cell
pretreat
luteolin
dmso
min
infect
ngml
assess
effect
luteolin
viru
entri
h
infect
accumul
intracellular
viral
capsid
quantifi
elisa
cell
lysat
posit
control
entri
inhibit
pretreat
tzmbl
cell
blocker
amd
infect
luteolin
pretreat
signific
effect
entri
compar
untreat
infect
cultur
fig
rule
possibl
contamin
cellmembranebound
viru
particl
cell
lysat
test
level
cell
supernat
hivsup
h
infect
found
bare
detect
level
fig
preced
result
show
luteolin
inhibit
infect
independ
viral
entri
investig
whether
luteolin
effect
viral
revers
transcript
infect
tzmbl
cell
h
treat
luteolin
monitor
level
reversetranscrib
intracellular
dna
h
infect
use
realtim
pcr
situat
unlik
use
azt
revers
transcriptas
inhibitor
posit
control
treat
infect
tzmbl
cell
luteolin
significantli
alter
amount
revers
transcrib
dna
fig
suggest
luteolin
unabl
annihil
viral
revers
transcript
investig
effect
luteolin
viral
integr
first
test
viral
integr
kinet
vsvpseudotyp
jurkat
cell
h
use
semiquantit
aluintegr
pcr
gapdh
intern
control
minimum
pcr
amplif
cycl
optim
obtain
amplif
product
linear
log
phase
densitometr
analysi
amplifi
pcr
product
show
viral
integr
rapid
jurkat
cell
start
within
h
infect
fig
consist
earlier
find
howev
result
suggest
peak
integr
level
reach
h
infect
slightli
longer
earlier
studi
differ
could
due
use
differ
strain
studi
test
effect
luteolin
viral
integr
infect
jurkat
cell
vsvpseudotyp
treat
cell
either
luteolin
vehicl
time
rang
h
h
viral
infect
monitor
gfp
express
viral
integr
use
alultr
pcr
describ
fig
e
parallel
use
integrasedefect
mutant
control
compar
vehicl
control
luteolinmedi
suppress
express
evid
irrespect
time
infect
treatment
initi
h
fig
weak
suppress
integr
signal
compar
untreat
infect
cell
fig
contrast
previou
report
show
exclus
effect
viral
integr
intriguingli
suppress
infect
cell
treat
luteolin
h
postinfect
suggest
luteolin
inhibitori
effect
life
cycl
mainli
exclus
postintegr
stage
given
integr
alreadi
complet
within
h
postinfect
fig
explor
effect
luteolin
postintegr
step
life
cycl
investig
replic
independ
viral
dna
integr
transfect
tzmbl
cell
dna
express
vector
treat
cell
luteolin
vehicl
control
dmso
monitor
viral
gene
express
use
ltrluciferas
assay
system
tat
express
dna
drive
ltrluciferas
express
quantifi
luminometr
luteolin
treatment
markedli
inhibit
gene
express
least
tat
express
compar
control
tzmbl
report
cell
fig
given
plasmid
dna
express
vector
replic
independ
viral
dna
integr
evid
luteolin
inhibit
either
tat
express
tat
function
ltr
level
dna
integr
valid
plasmid
dna
express
result
infect
studi
vsvpseudotyp
wildtyp
virus
envelopedefici
virus
use
tzmbl
report
cell
compar
control
luteolintr
report
cell
profoundli
suppress
tatregul
luciferas
signal
similar
plasmid
dna
transfect
fig
suggest
abort
viral
replic
dmso
control
also
show
suppress
luciferas
signal
dna
transfect
vsvviru
infect
tzmbl
cell
one
possibl
dmso
affect
luciferas
express
either
mrna
level
via
cmv
promot
howev
confirm
inhibit
result
magi
cell
hela
cell
use
gfp
viral
marker
transfect
cell
recombin
plasmid
dna
vector
express
gfp
treat
luteolin
h
h
transfect
monitor
gfp
express
viral
antigen
supernat
find
luteolin
treatment
suppress
fig
c
suggest
inhibit
dna
integr
step
convinc
small
inhibit
dmsotreat
infect
cultur
dna
transfect
report
cell
made
possibl
effect
viral
vsv
endocytosi
howev
underestim
true
effect
luteolin
corrobor
inhibit
wildtyp
infect
dnamedi
ltr
transactiv
postintegr
viral
state
without
inhibitori
effect
dmso
antivir
activ
luteolin
clearli
shown
infect
studi
wherein
dmso
confer
antivir
activ
result
rule
addit
effect
dmso
luteolin
hiv
inhibit
thu
far
luteolinmedi
suppress
ltrluciferas
activ
demonstr
plasmid
dna
transfect
infect
suggest
luteolin
may
confer
antivir
activ
function
level
tatltr
function
tat
express
subcellular
local
downstream
viral
proteas
examin
luteolinmedi
inhibit
integr
stage
experi
latent
infect
cell
genom
contain
gfp
gene
cell
contain
proviru
latent
state
without
viral
gene
express
includ
gfp
induct
activ
trichostatin
histon
deacetylas
inhibitor
howev
viral
reactiv
initi
cell
start
express
gfp
releas
viru
extracellularli
cell
pretreat
luteolin
dmso
h
viral
reactiv
initi
use
ngml
reactiv
latent
infect
attenu
treatment
luteolin
demonstr
reduct
gfp
express
releas
viru
induct
period
fig
indic
luteolin
effect
postvir
dna
integr
stage
viral
transcript
translat
tat
function
activ
tat
function
activ
impair
latent
model
gfp
express
includ
viral
protein
depend
tat
function
eventu
impair
activ
reduc
infect
cultur
supernat
taken
togeth
multipl
line
evid
indic
luteolin
confer
activ
inhibit
transcript
translat
process
proteas
howev
given
find
gfp
express
reduc
reactiv
latent
infect
acut
viral
infect
data
point
toward
transcript
inhibit
translat
fig
expect
crippl
viral
proteas
gfp
clone
env
nef
gene
express
independ
viral
proteas
activ
depend
tat
transcript
valid
infect
data
examin
tat
function
use
tat
express
vector
rule
viral
protein
mimic
express
tat
packag
lentiviralvector
express
tat
protein
pseudotyp
vsv
envelop
vsvtat
use
vsvtat
viral
particl
transduct
svgaltrgfp
report
cell
express
egfp
control
ltr
parallel
vsvpseudotyp
use
posit
control
luteolin
treatment
follow
transduct
vsvtat
viru
particl
led
suppress
ltrmediat
gfp
express
fig
suggest
compromis
tat
function
either
protein
express
level
ltrtransactiv
level
corrobor
result
use
tzmbl
report
cell
transfect
pcdnatat
express
vector
wherein
tat
control
cmv
promot
follow
treatment
differ
concentr
luteolin
result
dosedepend
suppress
ltrluciferas
express
occur
vehicletr
untreat
cultur
fig
investig
whether
luteolin
affect
tat
express
level
transfect
tzmbl
cell
tat
express
vector
pcdnatat
treat
either
luteolin
vehicl
luteolin
treatment
affect
tat
protein
level
analyz
western
blot
fig
indic
ltr
transactiv
fig
c
restrict
tat
function
level
parallel
cotransfect
tat
sirna
tat
express
vector
pcdnatat
posit
control
observ
suppress
tat
express
vehicl
control
fig
variat
transcript
activ
tat
protein
among
subtyp
predomin
attribut
sequenc
variabl
ntermin
activ
domain
amino
acid
especi
region
bind
cation
engag
cyclin
tat
subtypec
e
preval
asia
africa
report
exhibit
higher
transactiv
tar
rna
bind
capac
subtypeb
preval
north
america
europ
henc
investig
whether
luteolinmedi
suppress
tatmedi
ltrtransactiv
extend
differ
subtyp
transfect
cladeb
c
tat
express
vector
pcdnatat
vector
abund
express
tat
protein
found
tzmbl
cell
fig
inset
level
ltrtransactiv
similar
compar
control
observ
western
blot
fig
experi
luteolin
treatment
profoundli
inhibit
ltrmediat
luciferas
express
cladeb
c
tat
transfect
cell
fig
parallel
transcript
inact
mutant
delet
nuclear
local
signal
use
neg
control
demonstr
basal
luciferas
activ
empti
vector
pcdna
transfect
tzmbl
cell
given
tat
bona
fide
nuclearnucleolar
protein
investig
whether
luteolin
affect
subloc
thu
crippl
ltractiv
transfect
hela
cell
use
tatha
vector
h
transfect
treat
luteolin
dmso
left
untreat
h
transfect
cell
immunostain
tat
nucleophosmin
nucleolar
protein
nuclei
examin
tat
local
tat
subcellular
nuclearnucleolar
local
unaffect
luteolin
dmso
mock
treat
cell
fig
indic
viral
transactiv
protein
function
impair
ltrfunction
level
includ
either
tat
bind
tar
rna
cyclin
inhibit
critic
factor
includ
involv
hiv
transcript
fig
observ
confirm
luteolin
confer
activ
tatltr
transactiv
level
transcript
step
viral
integr
step
howev
investig
action
luteolin
need
deciph
detail
mechan
tatmedi
ltr
inhibit
current
investig
interact
tat
ltr
host
transcript
factor
well
modif
tat
presenc
luteolin
sever
compound
quinolin
well
stilben
purinederiv
report
show
antihiv
activ
inhibit
tattar
interact
compound
flavipiridol
rescovtin
acridin
target
compon
ptefb
complex
recent
coumarin
deriv
shown
potent
inhibit
hiv
tat
function
concentr
repress
support
possibl
luteolin
lead
develop
potent
deriv
inhibit
hiv
concentr
therefor
sever
activ
deriv
luteolin
shown
potent
antioxid
antiinflammatori
properti
need
investig
activ
intriguingli
quercetin
luteolin
analogu
shown
repress
proinflammatori
macrophag
would
interest
determin
whether
luteolin
effect
one
caveat
luteolin
may
complement
combin
antihiv
therapi
prevent
synthesi
viral
protein
avail
proteas
step
would
enhanc
potenc
proteas
inhibitor
eventu
lead
reduc
viru
assembl
releas
conclus
result
report
cell
primari
lymphocyt
indic
luteolin
crippl
tat
function
may
critic
compon
antiretrovir
combin
therapi
infect
addit
luteolin
cross
bloodbrain
barrier
shown
confer
neuroprotect
effect
via
inhibit
neuroinflamm
howev
concentr
luteolin
found
inhibitori
studi
upper
therapeut
rang
investig
need
determin
whether
concentr
achiev
vivo
investig
signific
luteolin
antihiv
drug
whether
act
synerg
lower
concentr
futur
goal
howev
laid
foundat
develop
luteolin
deriv
nanomolar
rang
may
could
inhibit
current
investig
abil
flavonoid
deriv
inhibit
hiv
nano
molar
rang
human
peripher
blood
mononuclear
cell
pbmc
separ
whole
blood
new
york
blood
bank
use
histopaqu
sigma
st
mo
wash
three
time
phosphatebuff
salin
pb
cultur
fb
contain
rpmi
previous
describ
tzmbl
hela
cell
jurkat
cell
obtain
aid
reagent
refer
program
nih
tzmbl
svgaltrgfp
cell
grown
dmem
jurkat
cell
grown
rpmi
mm
lglutamin
rpmi
gibcobrl
supplement
fb
penicillin
streptomycin
amphotericin
b
gibcobrl
obtain
chemic
reagent
sigma
st
loui
mo
stock
luteolin
quercetin
myricetin
prepar
dimethyl
sulphoxid
dmso
flavonoid
use
studi
puriti
rabbit
polyclon
antiha
antibodi
purchas
santa
cruz
biotechnolog
mous
nucleophosmin
antibodi
abcam
alexa
conjug
goat
antirabbit
igg
alexa
conjug
goat
antimous
igg
invitrogen
purchas
mous
monoclon
anti
antibodi
sigma
obtain
nl
subtyp
c
tat
vsvg
express
plasmid
nation
institut
health
nih
aid
reagent
refer
program
use
describ
use
integras
mutant
fulllength
subtyp
b
tat
amino
acid
subclon
pcdnatat
deriv
lentivir
vector
plvx
clontech
cmv
promot
packag
vsv
envelop
describ
earlier
ha
tag
insert
cterminu
fulllength
subtyp
b
subtyp
c
tat
along
ecori
xhoi
restrict
site
pcr
amplif
amplicon
clone
vector
similarli
subtyp
b
tat
ha
tag
subclon
bicistron
vector
clontech
function
inact
subtyp
b
mutant
creat
delet
nuclear
local
signal
amino
acid
clone
ha
tag
vector
ecori
xhoi
site
insert
confirm
dna
sequenc
long
termin
repeat
ltr
driven
gfp
construct
creat
replac
cmv
promot
vector
clontech
ltr
promot
sali
smai
stabli
transfect
svga
cell
full
length
dna
lentivir
vector
plvx
express
tat
packag
cell
describ
previous
briefli
transfect
hiv
lentivir
express
vector
dna
per
mm
cultur
dish
bd
falcon
use
lipofectamin
invitrogen
similarli
pseudotyp
provir
dna
vsvg
envelop
use
vsvg
construct
pseudotyp
lentivir
vector
cell
transfect
plvxtat
plvx
pcmvtat
pgagpol
pcmvrev
pvpr
pvsvg
use
lipofectamin
supernat
contain
viral
particl
harvest
h
transfect
centrifug
g
min
remov
cellular
debri
viral
stock
treat
iuml
rnasefre
dnase
min
room
temperatur
stock
filter
store
ml
aliquot
viral
titer
determin
elisa
zeptometrix
buffalo
ny
transduc
svgaltrgfp
report
cell
infect
either
tzmbl
jurkat
cell
done
tissu
cultur
plate
falcon
ngml
antigen
h
infect
cell
wash
twice
optimem
replac
complet
medium
contain
fb
next
day
medium
replac
remov
inputadsorb
viru
particl
releas
period
collect
supernat
third
fifth
day
infect
antigen
monitor
infect
cultur
supernat
quantit
elisa
zeptometrix
gfp
express
monitor
imag
captur
digit
camera
fluoresc
microscop
nikon
primari
human
lymphocyt
cultur
pbmc
stimul
pha
ngml
infect
hiv
h
wash
product
viru
infect
monitor
day
infect
elisa
tzmbl
cell
transfect
next
day
treat
luteolin
dmso
cell
harvest
h
transfect
lyse
ripa
buffer
sigma
contain
proteas
inhibitor
cocktail
pierc
total
protein
sampl
analyz
sdspage
protein
band
transfer
polyvinyliden
difluorid
pvdf
membran
biorad
block
membran
block
buffer
nonfat
dri
milk
tween
pb
h
room
temperatur
overnight
membran
probe
rabbit
polyclon
antibodi
ha
peptid
santa
cruz
biotechnolog
intern
control
mous
monoclon
antibodi
beta
actin
dilut
sigma
three
wash
tween
pb
membran
incub
antirabbit
igg
secondari
antibodi
conjug
horseradish
peroxidas
biorad
block
buffer
h
room
temperatur
wash
membran
three
time
tween
pb
develop
use
chemiluminesc
detect
kit
ecl
ge
healthcar
tat
level
quantifi
densitometr
analysi
use
imag
j
softwar
nih
normal
sampl
done
two
level
use
equal
protein
concentr
load
follow
actin
level
immunofluoresc
stain
done
describ
previous
hela
cell
seed
slide
flasket
nunc
denmark
transfect
ng
pcdnatatha
express
vector
use
lipofectamin
h
transfect
cell
fix
paraformaldehyd
min
cell
wash
twice
pb
permeabil
triton
vv
pb
min
slide
overlaid
primari
antibodi
ha
rabbit
monoclon
nuclear
maker
antibodi
dilut
slide
kept
overnight
parallel
antibodi
use
isotyp
antibodi
control
slide
wash
three
time
pb
overlaid
conjug
goatantirabbit
conjug
goatantimous
incub
min
two
wash
nuclei
stain
use
hoechst
min
slide
mount
fluoromount
sigma
aqueou
gel
mount
medium
slide
examin
nikon
fluoresc
microscop
imag
acquir
magnif
infect
tzmbl
cell
ngml
transfect
tat
express
vector
use
lipofectamin
invitrogen
either
plate
treat
cell
luteolin
vehicl
control
dna
concentr
transfect
normal
use
empti
control
vector
pcdna
h
treatment
lyse
cell
use
report
lysi
buffer
promega
put
one
freezingthaw
cycl
cell
lysat
use
monitor
luciferas
activ
reaction
use
readyglow
firefli
luciferas
substrat
promega
quantifi
luminesc
optilux
black
plate
falcon
use
multimod
micropl
reader
biotek
instrument
calcul
percent
ltr
luciferas
activ
rel
luciferas
unit
normal
cell
control
detect
viral
dna
synthesi
revers
transcript
infect
studi
realtim
pcr
describ
earlier
briefli
harvest
dna
infect
cell
use
dnazol
invitrogen
cell
remov
trypsin
wash
twice
pb
ad
ml
dnazol
cell
pellet
dna
precipit
ad
ethanol
remov
spool
pipett
tip
wash
ethanol
dna
dissolv
mm
naoh
ph
spectrophotometr
quantifi
amount
viral
dna
sampl
quantifi
realtim
pcr
use
tat
genespecif
primer
follow
primer
set
use
tat
forward
tat
revers
gapdh
forward
gapdh
revers
briefli
ng
genom
dna
use
pcr
reaction
mix
triplic
pmol
primer
sybr
green
sa
bioscienc
cycl
program
amplif
min
follow
cycl
sec
sec
sec
reaction
run
realtim
pcr
system
biorad
data
collect
analyz
use
biorad
cfx
manag
softwar
v
ct
valu
calcul
gene
normal
rel
gapdh
express
result
present
mean
sem
two
separ
experi
fold
express
untreat
control
calcul
method
examin
dna
integr
semiquantit
nest
integr
pcr
done
describ
previous
slight
modif
follow
primer
use
first
round
amplif
tgctgggattacagg
primer
second
round
use
ng
genom
dna
templat
amplif
first
set
pcr
primer
pcr
mix
amplif
cycl
min
follow
cycl
sec
sec
sec
nest
step
first
pcr
product
use
templat
reaction
volum
duplic
amplifi
cycl
use
similar
pcr
protocol
note
earlier
sampl
set
gapdh
amplifi
intern
control
ng
genom
dna
templat
use
cycl
program
min
follow
cycl
denatur
sec
sec
sec
amplifi
pcr
product
separ
visual
agaros
gel
quantif
densitometr
analysi
done
use
imag
j
softwar
nih
gapdh
use
normal
percent
integr
dna
calcul
rel
posit
control
h
infect
given
tzmbl
hela
cell
seed
plate
densiti
jurkat
cell
seed
densiti
per
well
cultur
cell
overnight
next
day
treat
cell
luteolin
control
triplic
h
measur
viabil
cell
remov
cultur
medium
ad
pb
contain
cell
count
reagent
dojindo
molecular
technolog
md
h
incub
collect
supernat
measur
absorb
nm
wavelength
multimod
micropl
reader
biotek
instrument
vt
percent
viabil
calcul
odtestodcel
control
human
pbmc
mtt
assay
done
ad
mtt
reagent
sigma
mgml
stock
prepar
pb
cell
incub
mtt
reagent
h
isopropanol
ad
dissolv
formazan
crystal
absorb
monitor
nm
wavelength
micropl
reader
biotek
instrument
result
repres
mean
sem
bar
graph
plot
use
sigma
plot
associ
p
valu
treatment
group
compar
control
statist
analysi
done
use
origin
softwar
signific
two
group
calcul
use
twotail
student
ttest
follow
oneway
analysi
varianc
p
consid
signific
